Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Protected Drugs Represent More than 50% of Bayer Yakuhin Sales in 2012, Over 60% Eyed by 2014: Pres. Brunn
April 4, 2013
- Mochida Aims at Sales of 104 Billion Yen in FY2015
April 4, 2013
- Presidents of Pharmaceutical Companies Stress Globalization, Compliance in Welcoming Ceremonies for New Employees
April 4, 2013
- Nihon Chouzai to Make Choseido Subsidiary, to Sell Its Products Through Nihon Generic
April 4, 2013
- Plavix Rises to 3rd Place in Domestic Ethical Drug Market in 2012, Could Take No. 1 Spot This Year
April 4, 2013
- MSD Reports Downturn in Profits for 2012 Despite 2.7% Growth in Sales
April 3, 2013
- AZ K.K. Reports 5.1% Decline in 2012 Sales; Sales of Omepral and Casodex Down
April 3, 2013
- Bayer Yakuhin Reports Nearly 20% Drop in Operating Profit Despite Growth in Sales of Zetia
April 3, 2013
- Abbott Japan Names Mr Sakamoto as President, Mr Honda as Vice President
April 3, 2013
- Janssen Poised to Keep Up Double-Digit Growth, Focus on 5 Therapeutic Areas: Japan Pres. Goodwin
April 3, 2013
- Kaketsuken also Files NDA for Cell Culture-Based New Influenza Vaccine
April 3, 2013
- Taiho Assigns 54 Oncology MRs according to Cancer Type
April 3, 2013
- AZ Takes Over Rights to Byetta and Bydureon; Bydureon Expected to Be Launched in May
April 2, 2013
- DSP Signs Agreement with Edison Pharmaceuticals of US for Mitochondrial Disease Treatments
April 2, 2013
- Gabriel Baertschi Takes Over as President of AZ K.K.
April 2, 2013
- MTPC Obtains Approval of SGLT-2 Inhibitor Canagliflozin in US
April 2, 2013
- 3 Companies’ Midterm Plans Foresee Poor Outlook for Domestic Market with “For-Reference-Only Figures,” “No Figures,” “Zero Growth”
April 2, 2013
- Mr Ninomiya Appointed as New President, Mr Mitani Exits to Become Advisor: Novartis Pharma
April 1, 2013
- Announcement: 6th annual Marketing Excellence Japan 2013 – Hilton Tokyo, May 14 – 15
April 1, 2013
- Dainippon Sumitomo Pharma Ties Up with Venture Company to Commercialize iPS Cell Therapy for Retinal Disease
April 1, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…